Synergetics USA

Deutsche Bank is out with its report today on Synergetics USA (NASDAQ: SURG), maintaining Buy. In a note to clients, Deutsche Bank writes, "In F2012 we forecast 50% EPS expansion to $0.33. That implies a 16x PE multiple for what becomes the current fiscal year in just two months (August). Based on...

Benchmark is out with its report today on Synergetics USA (NASDAQ: SURG), raising its PT from $6 to $7. In a note to clients, Benchmark writes, "We are raising our price target to $7.00 from $6.00 based on increasing our F2012 EPS forecast to $0.33 from $0.29, and increasing our valuation multiple...